SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
RAPT Therapeutics, Inc. (RAPT) .
本页证实的标准:
- VALUE (10/100, 未通过) — 分析师共识目标价暗示当前价格存在下行风险 ($30.71, 47.1%).
- 分析师共识目标价 $30.71 (-47.1% 下行风险) — 分析师认为当前价格水平存在明显下行风险。
SharesGrow 综合评分： 24/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
10/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — RAPT
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$-3.19
每股账面价值$0.00
每股营收$0.00
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$30.71 (-47.1%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2017 |
$-2.01 |
$0.00 |
$-29.12M |
- |
| 2018 |
$-2.09 |
$0.00 |
$-36.15M |
- |
| 2019 |
$-1.97 |
$0.00 |
$-43M |
- |
| 2020 |
$-2.19 |
$5.04M |
$-52.89M |
-1049% |
| 2021 |
$-2.49 |
$3.81M |
$-68.21M |
-1788.8% |
| 2022 |
$-2.52 |
$1.53M |
$-81.88M |
-5362.2% |
| 2023 |
$-3.05 |
$0.00 |
$-116.8M |
- |
| 2024 |
$-3.19 |
$0.00 |
$-129.87M |
- |
